2 ▁months . ▁ ▁The ▁E MA ▁approved ▁the ▁R TS , S ▁v acc ine ▁in ▁July ▁ 2 0 1 5 , ▁with ▁a ▁recommendation ▁that ▁it ▁be ▁used ▁in ▁Africa ▁for ▁b ab ies ▁at ▁risk ▁of ▁getting ▁mal aria . ▁ ▁R TS , S ▁was ▁the ▁world ' s ▁first ▁mal aria ▁v acc ine ▁to ▁get ▁appro val ▁for ▁this ▁use . ▁After ▁additional ▁regul atory ▁dec isions ▁by ▁the ▁World ▁Health ▁Organ ization , ▁and ▁individual ▁African ▁country ▁govern ments , ▁a ▁" roll ▁out " ▁of ▁the ▁product ▁could ▁come ▁as ▁early ▁as ▁ 2 0 1 7 . ▁ ▁Pre lim inary ▁research ▁suggests ▁that ▁delayed ▁fraction al ▁dos ing ▁could ▁increase ▁the ▁v acc ine ' s ▁effic acy ▁up ▁to ▁ 8 6 %. ▁ ▁On ▁ 1 7 ▁November ▁ 2 0 1 6 , ▁W HO ▁announced ▁that ▁the ▁R TS , S ▁v acc ine ▁would ▁be ▁rolled ▁out ▁in ▁pilot ▁projects ▁in ▁ 3 ▁countries ▁in ▁sub - S ah aran ▁Africa . ▁The ▁pilot ▁programme , ▁coordin ated ▁by ▁W HO , ▁will ▁assess ▁the ▁extent ▁to ▁which ▁the ▁v acc ine ’ s ▁protect ive ▁effect ▁shown ▁in ▁advanced ▁clin ical ▁tri als ▁can ▁be ▁rep licated ▁in ▁real - life ▁settings . ▁Specifically , ▁the ▁programme ▁will ▁evaluate ▁the ▁feas ibility ▁of ▁deliver ing ▁the ▁required ▁ 4 ▁dos es ▁of ▁the ▁v acc ine ; ▁the ▁impact ▁of ▁the ▁v acc ine ▁on ▁lives